Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAetna TMS Coverage Prior Auth Policy Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0469

    Transcranial Magnetic Stimulation and Cranial Electrical Stimulation

    Customize your policy alerts

    Sign up for Aetna Policy 0469 alerts

    Get alerted when Policy 0469 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, coverage, and investigational determinations for TMS and cranial electrical stimulation for psychiatric and other indications, and lists applicable billing codes and clinical background. Applies to Aetna members and treating providers.

    Policy Summary
    PayerAetna
    PolicyTranscranial Magnetic Stimulation and Cranial Electrical Stimulation
    Policy CodePolicy 0469
    Change TypeNo material clinical or coverage changes in this revision.
    Effective DateApr 13, 2001
    Last ReviewFeb 16, 2024
    Next Review DateMay 9, 2024
    Key ActionObtain prior authorization documenting prior adequate antidepressant trials and psychiatrist oversight before TMS is authorized.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18Minimum age
    30+6Max sessions/course
    2 antidepressants (>=8w)Required trials
    ExperimentalCES stance
    25% vs 9%rTMS vs sham response
    24RCTs in TRD meta-analysis

    Coverage Criteria and Evidence Summaries

    Initial TMS Coverage Criteria

    Covered when ALL of the following are met:

    Age and device: Member is ≥ 18 years and TMS is administered by an FDA‑cleared device and used per FDA‑labeled indications
    Diagnosis: Confirmed diagnosis by a psychiatrist of severe major depressive disorder (single or recurrent) without psychosis, documented by standardized rating scales with baseline and ongoing measurement

    Examples: BDI, HDRS, MADRS

    Prior treatment trials: Inadequate response during the current depressive episode within the past 5 years to either: (a) two antidepressants from at least two different classes at maximally tolerated labeled dose each for ≥8 weeks, OR (b) augmentation therapy with the primary antidepressant for ≥8 weeks (augmenting agent from different class if antidepressant)Each antidepressant trial: ≥8 weeks at or above minimal effective therapeutic dose
    Policy Summary
    PayerAetna
    PolicyTranscranial Magnetic Stimulation and Cranial Electrical Stimulation
    Policy CodePolicy 0469
    Change TypeNo material clinical or coverage changes in this revision.
    Effective DateApr 13, 2001
    Last ReviewFeb 16, 2024
    Next Review DateMay 9, 2024
    Key ActionObtain prior authorization documenting prior adequate antidepressant trials and psychiatrist oversight before TMS is authorized.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummariesBilling and Diagnosis CodesPrior Authorization, Documentation, and Denial TriggersClinical and Technical BackgroundDefinitions and TerminologyTreatment Modalities and ModificationsSession Limits and SchedulingRevision History and References

    Current episode defined as most recent onset of acute symptoms

    Treatment course limits: Planned treatment consists of a maximum of 30 sessions (5 days/week for ~6 weeks) plus up to 6 tapering sessions (6 sessions over 3 weeks); treatments beyond 36 sessions require additional review for medical necessityMaximum 36 sessions per course

    Evidence lacking for benefit beyond 36 sessions

    Provider requirements: Order must be written by a psychiatrist (MD/DO) or behavioral health nurse practitioner who examines the patient, oversees motor threshold determinations, mapping, treatment planning, certifies direct supervision, and is immediately available; TMS operator must be trained and present in the treatment room and able to monitor/manage adverse events including seizure

    Psychiatrist oversight and operator qualifications required

    TMS Re-treatment Criteria

    Re-treatment covered when ALL of the following are met:

    Meets initiation criteria: Member continues to meet initial TMS initiation/coverage criteria
    Relapse after prior response: Member has relapsed following prior TMS despite other appropriate treatments (eg, psychotherapy, pharmacotherapy) as applicable
    Prior response duration: Member previously had at least 50% reduction in depressive symptoms with TMS maintained for at least 2 months after the prior TMS course; repeat TMS within 60 days of prior course is not medically necessary≥50% symptom reduction maintained ≥2 months; no repeat within 60 days

    Documentation of prior response required (standardized rating scales)

    Contraindications and Experimental/Investigational

    TMS is considered not medically necessary or experimental/investigational for persons with ANY of the following contraindications or uses:

    Contraindications: Active substance abuse with known abuse potential within the last 90 days; suicidal members; metal implant in or around the head (eg, aneurysm clip/coil, metal plate, ocular implant, stent); neurologic conditions such as cerebrovascular disease, dementia, history of repetitive or severe head trauma, increased intracranial pressure, or CNS tumors; presence of implanted electronic devices (eg, pacemaker/defibrillator, cochlear implant, deep brain stimulator, implantable infusion pump, spinal cord stimulator, vagus nerve stimulator)

    Severe cardiovascular disease requires cardiology clearance

    Experimental/Investigational uses: Adjunctive use of ketamine with TMS; combined TMS+EEG for unconsciousness evaluation; non‑standard high‑hertz TMS under sedation; navigated TMS for motor mapping/treatment planning in neurologic disease; TMS maintenance therapy beyond the specified 30+6 sessions; and TMS or CES for listed indications (including but not limited to Alzheimer's disease, ALS, anxiety disorders, bipolar disorder, bulimia nervosa, chronic pain syndromes including central post‑stroke pain, fibromyalgia, migraine, multiple sclerosis symptomatic uses, neurodevelopmental disorders, epilepsy/status epilepticus, addiction, OCD except where FDA‑cleared dTMS for OCD applies, and cranial electrical stimulation for any indication)

    Extensive list enumerated in policy; CES considered experimental for any indication

    Coverage rationale and clinical criteria

    Evidence-based coverage considerations drawn from trials and regulatory language:

    TMS candidate prerequisites: Adult with major depressive disorder who has failed to achieve satisfactory improvement from ≥1 prior antidepressant trial in the current episode and who can adhere to a multi‑week daily treatment course; informed consent should note limited durability evidence>=1 failed antidepressant trial

    Reflects FDA clearance populations and pivotal trial enrollment

    Expected outcomes and limitations: rTMS/dTMS may provide short‑term clinical response and modest remission rates versus sham; durability beyond weeks to months is uncertain and comparative effectiveness versus ECT or optimized pharmacotherapy remains unclear

    Supported by systematic reviews and technology assessments; interpret cautiously

    Evidence summary and coverage considerations

    Coverage considerations should reflect the low strength and inconsistent evidence; key findings from systematic reviews and technology assessments:

    Key evidence points: 1) Multiple assessments found inconsistent or low‑quality evidence for TMS effectiveness; 2) Short‑term trials show small statistically significant differences versus sham for some response measures but inconsistent remission benefits; 3) Durability of benefit beyond weeks to months is uncertain; 4) Comparative effectiveness versus ECT or optimized pharmacotherapy is unclear; 5) Many trials have methodological issues (small size, crossovers, dropouts, possible publication bias)

    Supports cautious, criteria‑based coverage and requirement for clear prior‑treatment documentation

    Maintenance and retreatment evidence

    Studies addressing maintenance or retreatment show mixed observational and some randomized data:

    Maintenance findings: Observational cohorts (eg, Dunner et al., Richieri et al.) suggest possible durability or reduced relapse with maintenance or retreatment but are limited by open‑label design and confounding; a randomized 12‑month study (Wang et al.) found rTMS‑containing regimens reduced relapse versus antidepressant alone but lacked sham control; protocol‑defined intermittent rescue TMS recaptured response in many patients in follow‑up studies

    Maintenance benefit remains uncertain; document acute response and plan for maintenance/retreatment when requested

    Neuropathic and Orofacial Pain

    Evidence supporting use in neuropathic pain and orofacial pain:

    ref':'b0_6
    title':'Neuropathic and Orofacial Pain'

    Central Post-Stroke Pain

    Central post‑stroke pain:

    ref':'b0_7
    title':'Central Post-Stroke Pain'

    Fibromyalgia

    Fibromyalgia:

    ref':'b0_9
    title':'Fibromyalgia'

    Migraine

    Migraine (acute and preventive):

    ref':'b0_10
    title':'Migraine'

    Parkinson Disease

    Parkinson disease (motor and non‑motor symptoms):

    ref':'b0_11
    title':'Parkinson Disease'

    Parkinson Disease — evidence summary

    Evidence‑based findings from trials and systematic reviews:

    ref':'b0_12
    title':'Parkinson Disease — evidence summary'

    Tinnitus — evidence summary

    Tinnitus — evidence summary:

    ref':'b0_13
    title':'Tinnitus — evidence summary'

    Anxiety Disorders (including PTSD, GAD) — evidence summary

    Anxiety disorders (including PTSD, GAD) — evidence summary:

    ref':'b0_14
    title':'Anxiety Disorders (including PTSD, GAD) — evidence summary'

    Spasticity in MS — evidence summary

    Spasticity in MS — evidence summary:

    ref':'b0_15
    title':'Spasticity in MS — evidence summary'

    Bulimia Nervosa — evidence summary

    Bulimia nervosa — evidence summary:

    ref':'b0_16
    title':'Bulimia Nervosa — evidence summary'

    Schizophrenia (auditory verbal hallucinations and symptoms) — evidence summary

    Schizophrenia (auditory verbal hallucinations and symptoms) — evidence summary:

    ref':'b0_17
    title':'Schizophrenia (auditory verbal hallucinations and symptoms) — evidence summary'

    Stroke — evidence summary

    Stroke — evidence summary:

    ref':'b0_18
    title':'Stroke — evidence summary'

    Overall evidence posture

    Overall evidence posture:

    ref':'b0_19
    title':'Overall evidence posture'

    Areas with suggestive/positive findings

    Areas with suggestive/positive findings:

    Subcortical stroke motor recovery: Meta‑analyses found larger effect sizes for subcortical stroke and for low‑frequency rTMS over the unaffected hemisphere for upper limb motor outcomes
    Lower limb function: Meta‑analysis of 8 RCTs showed rTMS improved lower limb body function, activity, walking speed, and MEPs with short‑term benefits
    ref':'b0_20
    title':'Areas with suggestive/positive findings'

    Areas lacking sufficient evidence

    Areas lacking sufficient evidence:

    Routine rTMS for stroke: Cochrane review concluded current evidence does not support routine use of rTMS for stroke; further larger trials are needed
    ref':'b0_21
    title':'Areas lacking sufficient evidence'

    Safety and feasibility findings

    Safety and feasibility:

    ref':'b0_22
    title':'Safety and feasibility findings'

    Evidence summaries by indication

    Evidence summaries by indication (informational signals from studies):

    Stroke – lower limb and dysphagia: rTMS showed short‑term improvement in lower limb motor function (SMD≈0.66) and dysphagia (SMD≈0.65) but studies are small and heterogeneous; larger trials needed
    SCI – neuropathic pain: High‑frequency rTMS over motor cortex may reduce neuropathic pain after spinal cord injury; pooled RCTs (8 RCTs, 141 patients) show modest pain reduction (MD approx -0.81) with variable individual trial results
    Dementia/Alzheimer disease: TMS/tDCS can produce acute short‑duration cognitive effects; safety short‑term supported but clinical significance and long‑term risks unclear
    Disorders of consciousness: tDCS may transiently improve CRS‑R scores in minimally conscious state patients (Thibaut et al.); long‑term functional benefit unproven
    ref':'b0_23
    title':'Evidence summaries by indication'

    Coverage summary by clinical indication

    Coverage summary by clinical indication (informational):

    TBI and disorders of consciousness: tDCS and other NIBS show preliminary promise in improving measures of consciousness in MCS patients with transient effects; long‑term benefit unproven
    Addiction: rTMS/dTMS evidence is heterogeneous; considered experimental with some positive findings for nicotine, alcohol, and cocaine but optimal protocols and durability are uncertain
    Congenital hemiparesis (pediatrics): Primed LF‑rTMS combined with constraint‑induced movement therapy appears safe in small trials; efficacy not definitively shown
    Communication and swallowing disorders: Some RCTs report improvements in aphasia and dysphagia with rTMS versus sham, but optimal protocols and applicability remain uncertain
    Epilepsy/Status Epilepticus: Reports suggest potential seizure reduction in select cases but evidence is low quality and durability short‑lived; routine use not established
    ref':'b0_24
    title':'Coverage summary by clinical indication'

    Evidence summaries (informational)

    Evidence‑supported scenarios and findings (informational):

    nTMS for pre‑operative mapping: nTMS‑based mapping has been associated with changed surgical strategy and reduced post‑operative permanent motor deficits in meta‑analyses, but direct demonstration of improved long‑term patient outcomes is limited

    Lesion‑to‑tract distance (LTD) thresholds reported in some studies

    nTMS‑based DTI fiber tracking: nTMS‑based tractography reported lesion‑to‑tract distance cut‑offs associated with lower permanent aphasia risk (eg, AF >=8 mm; other language tracts >=11 mm)>=8 mm; >=11 mm

    May inform surgical risk stratification

    ref':'b0_25
    title':'Evidence summaries (informational)'

    dTMS for Obsessive-Compulsive Disorder (OCD)

    dTMS for Obsessive‑Compulsive Disorder (OCD) — evidence‑based coverage considerations:

    ref':'b0_26
    title':'dTMS for Obsessive-Compulsive Disorder (OCD)'

    1-Hz rTMS adjunctive treatment (observational data)

    Adjunctive 1‑Hz rTMS (observational) — OCD:

    ref':'b0_27
    title':'1-Hz rTMS adjunctive treatment (observational data)'

    Other indications (RLS, visual hallucinations, dementia differential, CRPS, PLP, bipolar, MS)

    Other indications — evidence summaries and stance (informational):

    Restless Legs Syndrome (RLS): AAN guideline: rTMS is possibly effective for moderate‑severe primary RLS (Level C); tDCS probably ineffective in drug‑naive women

    UpToDate does not list TMS as therapeutic option

    Visual hallucinations after stroke: Single‑case reports suggest multi‑day low‑frequency rTMS to occipital cortex may reduce chronic visual phosphene hallucinations; evidence is Class IV and preliminary
    Differential diagnosis AD vs FTD using TMS: TMS paired‑pulse paradigms showed high sensitivity/specificity in distinguishing AD from FTD in cohort studies, suggesting potential diagnostic adjunct pending replication

    Class III evidence

    CRPS and PLP: Systematic reviews identify altered cortical maps and preliminary therapeutic rTMS attempts for CRPS and phantom limb pain with limited patient numbers; evidence insufficient for routine coverage

    Further well‑designed trials needed

    Bipolar disorder (cognitive outcomes): Small randomized/pilot trials report selective cognitive domain improvements after short HF‑rTMS courses; sample sizes small and follow‑up limited
    ref':'b0_28
    title':'Other indications (RLS, visual hallucinations, dementia differential, CRPS, PLP, bipolar, MS)'

    Aetna considers TMS maintenance therapy — defined as treatment provided outside the established course of 30 sessions over 6 weeks plus 6 tapering sessions — to be experimental and investigational because effectiveness of ongoing maintenance protocols beyond the specified treatment course has not been established in the peer-reviewed literature.

    Multiple technology assessments (including BCBSA/TEC and CTAF) and HTA reports have judged repetitive TMS to have insufficient or low-quality evidencerTMS is considered experimental/insufficient evidence in contexts where demonstrable improved health outcomes or equivalence to established alternatives (e.g., augmentation strategies, ECT) are required.

    Some health technology assessment bodies (for example, the Galacian HTA Agency / AVALIA‑T) have explicitly concluded that transcranial magnetic stimulation is not currently recommended for depression because of uncertainty about clinical efficacy and limitations in the available evidence.

    Patients with psychotic depression were excluded from the cited dTMS randomized trial; prior trial evidence reported superiority of electroconvulsive therapy (ECT) over rTMS in this subgroup, and therefore ECT may be preferred for psychotic depression while TMS is not established in that population.

    The German S3 guideline update process did not recommend transcranial current stimulation and explicitly listed magnetic field therapy among treatments not recommended for fibromyalgia, reflecting guideline-level caution about these modalities for that indication.

    For a number of indications (for example, some tinnitus protocols and several anxiety disorders), randomized controlled trials and systematic reviews provide insufficient or conflicting evidence. Where trials are small, heterogeneous, or show no advantage over sham, these indications currently lack definitive support for routine coverage.

    Systematic reviews and Cochrane assessments conclude that the evidence does not support the routine use of rTMS or tDCS for stroke rehabilitation. Trials are heterogeneous and sample sizes are small, and therefore these interventions are considered experimental or investigational for routine post‑stroke recovery absent stronger RCT evidence and documented functional benefit.

    Repetitive TMS for amyotrophic lateral sclerosis (ALS) remains largely experimental; current reviews report insufficient evidence to support routine diagnostic or therapeutic use of rTMS in ALS.

    Evidence for rTMS in refractory status epilepticus and seizure suppression is limited to low‑quality observational reports; given uncertain efficacy and a small but nonzero seizure induction risk, routine use is not recommended and applications remain investigational.

    The Brainsway deep TMS (dTMS) system has device-specific contraindications: it is contraindicated in patients with metallic objects or implanted stimulators in or near the head (for example cochlear implants, deep brain stimulators, vagus nerve stimulators, other implanted electrodes, aneurysm clips/coils, stents, bullet fragments, jewelry, hair barrettes). Patients with a history of seizures and all patients must use ear protection during treatment.

    Pediatric guidance (UpToDate review) does not list TMS as a therapeutic option for pediatric OCD, and a cited real‑world dataset reported that dTMS for OCD was often not reimbursed by insurers, implying limited adoption and potential exclusion from coverage in pediatric settings.

    Cranial electrical stimulation (CES) randomized trials and systematic reviews provide insufficient evidence of clinically important effects for fibromyalgia, headache, neuromusculoskeletal pain, degenerative joint pain, depression, or insomnia; only low‑strength evidence suggests modest benefit for anxiety and depression, and overall CES is considered investigational for these indications.

    The aggregate review concluded there is insufficient evidence that CES produces clinically important benefits for pain syndromes, headache, mood disorders, or sleep disturbance; most trials were small, short duration, and at high risk of bias.

    TMS is considered not medically necessary for members with listed contraindications, including recent substance abuse within 90 days, active suicidal status, metal cranial implants, certain neurologic conditions (cerebrovascular disease, dementia, severe head trauma, CNS tumors), and the presence of implanted electronic devices (pacemaker, defibrillator, cochlear implant, DBS, infusion pump, spinal cord stimulator, VNS).

    Use of rTMS for indications where expectations of durable clinical benefit, comparative effectiveness versus alternatives, or adequate trial design/follow‑up are not met may be considered not medically necessary; lack of adequately powered randomized evidence or convincing health‑outcome improvements compared with sham or active alternatives supports cautious non‑coverage in those settings.

    Many systematic reviews and technology assessments note a lack of consistent, adequately powered randomized evidence showing improved patient‑important outcomes versus sham or established alternatives; this limitation underlies determinations that TMS is investigational for several indications.

    Some experts have concluded that TMS has no established role in the management of central pain, and use in chronic central pain syndromes is considered investigational pending higher‑quality evidence.

    Interventions for central post‑stroke pain and routine rTMS for fibromyalgia are supported by low‑to‑very‑low certainty evidence; pooled effects in some meta‑analyses were below minimal clinically important differences, so these applications remain experimental or not medically necessary for routine care.

    There are specific applications where sham‑controlled trials show no superiority of active stimulation (for example, continuous theta burst stimulation for chronic tinnitus in Plewnia et al., and rTMS for bulimia nervosa in Walpoth et al.); such negative randomized results indicate those protocols are not supported for routine clinical use.

    Use of rTMS as a routine, stand‑alone treatment for post‑stroke recovery is not supported by current Cochrane evidence; absent trial‑supported indication or clear documentation of concurrent rehabilitation and targeted outcomes, routine coverage is not recommended.

    For benign essential blepharospasm, small randomized data showed short‑lasting effects with rTMS compared with established botulinum toxin therapy; given transient benefit and time‑consuming nature of rTMS, routine clinical use is not recommended at this stage.

    Applications of rTMS for addiction remain experimental; systematic reviews identify heterogeneous small studies with preliminary signals (nicotine, alcohol, cocaine) but optimal parameters, durability, and high‑quality controlled evidence are lacking.

    The policy notes insufficient evidence that navigated TMS (nTMS) is an effective clinical diagnostic test; many studies are small and larger well‑designed investigations are required before routine diagnostic use can be supported.

    For complex regional pain syndrome (CRPS), phantom limb pain, and symptomatic uses in multiple sclerosis, the evidence is preliminary and insufficiently replicated; these indications remain investigational pending larger, well‑designed randomized trials.

    A randomized sham‑controlled multicenter dTMS trial in central neuropathic pain (ACC or PSI targets) did not demonstrate superiority versus sham for pain relief; while some secondary physiologic or mood measures changed, routine coverage for dTMS in central neuropathic pain is not supported by this evidence.

    An UpToDate review on schizophrenia maintenance therapy does not mention TMS as a management or therapeutic option, implying lack of established role for TMS in schizophrenia maintenance at present.

    Billing and Diagnosis Codes

    Covered CPT Codes (if selection criteria met)CPTCovered
    90867Therapeutic repetitive transcranial magnetic stimulation treatment; planning.
    90868Therapeutic repetitive transcranial magnetic stimulation treatment; delivery and management, per session.
    90869Subsequent motor threshold re-determination with delivery and management.
    CPT Codes Not Covered (examples)CPTNot Covered
    95700-95726Electroencephalogram (EEG) codes listed as not covered in context.
    95812Electroencephalogram (EEG) extended monitoring; 41-60 minutes.
    95813Electroencephalogram (EEG) extended monitoring; 61-119 minutes.
    HCPCS Covered if criteria metHCPCSCovered
    G0295Electromagnetic therapy, to one or more areas.
    HCPCS Codes Not Covered for Indications ListedHCPCSNot Covered
    A4596Cranial electrotherapy stimulation (CES) system supplies and accessories, per month.
    E0732Cranial electrotherapy stimulation (CES) system, any type.
    ICD-10 Codes Covered if Selection Criteria MetICD-10Covered
    F32.2Major depressive disorder, single episode, severe without psychotic features.
    F33.2Major depressive disorder, recurrent, severe without psychotic features.
    ICD-10 Codes Not Covered for Indications Listed (examples)ICD-10Not Covered
    C71.0-C71.9Malignant neoplasm of brain (listed among not-covered diagnoses).
    G40.0-G40.919Epilepsy and recurrent seizures (listed among not-covered diagnoses).
    G30.0-G30.9Alzheimer's disease (listed among not-covered diagnoses).
    Codes referencedmixed
    No codes listed
    Adequate antidepressant trial
    DefinitionEach antidepressant trial must be ≥ 8 weeks at or above the minimal effective therapeutic dose to qualify as an adequate trial
    Counting trialsTwo antidepressants from at least two different classes (different mechanisms) during the current episode are required unless qualifying augmentation strategy used
    Augmentation optionAugmentation therapy with the primary antidepressant for ≥ 8 weeks counts as an adequate trial; if the augmenting agent is an antidepressant it must be from a different class
    Max TMS sessions per course
    Standard course limitMaximum 30 sessions delivered 5 days/week over 6 weeks plus 6 tapering sessions (6 sessions over 3 weeks) — 36 sessions total
    Exceeding limitTreatments beyond 36 sessions may be reviewed for medical necessity; evidence lacking for benefit beyond 36 sessions
    Typical schedulingAcute treatment usually administered daily (5 days/week) for the 6-week course
    Lesion‑to‑tract distance (LTD)
    Arcuate fasciculus (AF) cutoffLesion‑to‑tract distance (LTD) for AF ≥ 8 mm
    Other language tracts cutoffLTD for superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus (ILF), uncinate (UC), or forceps of the frontal lobe (FoF) ≥ 11 mm
    PurposeCut-offs used for risk stratification to predict lower likelihood of surgery-related permanent aphasia

    Prior Authorization, Documentation, and Denial Triggers

    Prior Authorization

    Prior Authorization Required and Protocol Details

    Prior authorization is required for device‑based TMS therapies and documentation must demonstrate prior antidepressant treatment and treatment‑resistant status. Requests should include the indication, targeted brain region/modality (rTMS, dTMS, navigated TMS, tDCS/CES), proposed stimulation parameters (frequency, intensity relative to motor threshold, pulses/session, number of sessions, tapering plan), and the supervising psychiatrist’s order and oversight plan.

    • Device‑based TMS (rTMS/dTMS/navigated TMS) — anticipate prior authorization
    • Submission must specify modality, target region, stimulation frequency, intensity (eg, % of motor threshold), total pulses, sessions and tapering
    • Psychiatrist order certifying direct supervision and oversight of motor threshold determination
    Prior Authorization

    Prior Antidepressant Trials and Evidence of Treatment Resistance

    Prior authorization should document prior adequate antidepressant trials in the current depressive episode (typically within the past 5 years) including: two antidepressants from different classes at minimally effective therapeutic doses each for ≥8 weeks, and/or an adequate augmentation trial (defined below). Evidence of treatment resistance (failure of these trials) must be clear in the record.

    • Two antidepressants from ≥2 different classes, each ≥8 weeks at minimally effective dose
    • OR an augmentation strategy (see Appendix) used for ≥8 weeks counts as an adequate trial
    • Document dates, doses, tolerability, and source verification when possible (eg, pharmacy records)
    Prior Authorization

    Consider Prior Treatment Resistance and Alternatives

    Prior authorization reviewers should consider prior treatment resistance and prior trials when evaluating requests. When TMS is proposed after pharmacotherapy failure, document prior medication optimization, trials of augmentation strategies, intolerance or contraindications to alternatives (including ECT when relevant), and the rationale for choosing TMS.

    • Confirm whether ECT was considered or contraindicated — ECT may be preferred for some treatment‑resistant cases
    • Document prior medication strategies tried and whether augmentation was attempted
    • Describe why device TMS is being selected over other options
    Prior Authorization

    PA Recommended Given Limited Routine‑Use Evidence

    Because high‑quality evidence is limited or inconsistent for many non‑depression indications and for routine long‑term benefit, prior authorization is recommended for TMS/tDCS/CES uses outside clear FDA‑labeled indications. Reviewers should require submitted evidence and rationale for routine or extended use in investigational indications.

    • Routine use unsupported in several Cochrane and guideline reviews — require protocol and evidence for routine stroke, chronic pain, and other non‑MDD indications
    • PA recommended for investigational or off‑label indications (eg, addiction, TBI, epilepsy)
    Prior Authorization

    Prior Authorization for rTMS in SCI‑Associated Neuropathic Pain

    For spinal cord injury (SCI)–associated neuropathic pain, evidence is mixed and small RCTs produce inconclusive results. Prior authorization should require documentation of prior conservative therapies, the specific neuropathic pain diagnosis, proposed target (eg, M1), stimulation parameters, and evidence supporting trial use in the patient.

    • Document prior conservative therapies attempted and response
    • Specify stimulation site (eg, primary motor cortex or DLPFC), frequency, intensity, and number of sessions
    • Provide rationale and supporting literature when requesting coverage for SCI‑related neuropathic pain
    Prior Authorization

    Potential Prior Authorization for Investigational/Novel Uses

    Many indications remain investigational (eg, addiction, some pain syndromes, TBI, epilepsy applications beyond small studies). Payers should consider prior authorization for these novel uses and expect submission of supporting evidence and an a priori protocol describing outcomes and safety monitoring.

    • Treat addiction, TBI, and similar uses as experimental — require protocol and evidence submission
    • If used clinically, specify concomitant treatments and outcome measures in the PA request
    Prior Authorization

    Prior Authorization Likely Required for Device TMS

    Device‑based TMS treatments are likely to require prior authorization. The device must be FDA‑cleared for the requested indication and treatment should generally follow manufacturer protocols; deviations (including intensity adjustments) should be justified with evidence.

    • Confirm device clearance status for the indication (eg, NeuroStar for MDD; Brainsway for OCD)
    • Treatments should follow device labeling and manufacturer parameters unless supported by peer‑reviewed evidence
    Documentation Required

    Protocol Intensity Deviations Affect Efficacy

    Protocol intensity deviations can affect efficacy. Adequate stimulation intensity (commonly ~120% of individual motor threshold in trials) is important; lower intensities may reduce clinical response, and higher intensities must be within safety guidance.

    • Document planned intensity as % of motor threshold and how threshold will be determined
    • If intensity will be reduced for tolerability, provide rationale and expected effect on efficacy
    Denial Risk

    Potential Denial Trigger for Tinnitus rTMS Without Demonstrated Benefit

    Tinnitus studies show mixed results; some trials find no benefit versus sham. Requests for tinnitus rTMS should include evidence the proposed protocol has demonstrated benefit for the tinnitus subtype and clear outcome measures; absence of supportive evidence may be a denial trigger.

    • Document tinnitus subtype, prior therapies tried, and justification for the selected target and protocol
    • Cite randomized evidence showing benefit for the exact stimulation parameters and target region
    Denial Risk

    Routine Use Unsupported in Cochrane and Guideline Reviews

    Several Cochrane reviews and technology assessments do not support routine use of rTMS for some conditions (eg, stroke) due to limited or inconsistent evidence. Such findings may support prior authorization and denial decisions when robust RCT evidence is lacking.

    • Cochrane reviews found insufficient evidence to support routine rTMS for stroke
    • Use review conclusions as rationale for requiring PA and conservative coverage decisions
    Denial Risk

    Evidence Limitations May Affect Coverage

    Evidence limitations — small samples, short durations, heterogeneity, and risk of bias — may affect coverage decisions. Reviewers may deny requests when high‑quality comparative evidence (durability, patient‑centered outcomes) is absent for the requested indication or protocol.

    • Expect denials or requests for additional evidence for indications with low‑strength or inconsistent trial data
    • Large, long‑term RCTs and head‑to‑head comparisons (eg, vs ECT) strengthen the case for coverage
    Denial Risk

    Safety and Efficacy Limitations for Epilepsy Applications

    For epilepsy and status epilepticus applications, evidence is very limited, largely retrospective, with short‑lived responses and a small but measurable seizure induction risk. Routine use is not recommended and prior authorization should require detailed risk/benefit justification and safety monitoring plans.

    • Seizure induction risk estimated in pooled reports (~2–3%) — document baseline seizure frequency and potential confounders
    • For status epilepticus uses, provide case‑level evidence and plan for monitoring and relapse management
    Note

    No Explicit Universal Authorization Requirements Stated

    No single explicit universal authorization checklist is provided in the source documents; however, providers should anticipate PA for many TMS/device‑based interventions and submit comprehensive clinical documentation to support medical necessity.

    • There is no exhaustive PA code list in the sources — check payer‑specific PA forms and code lists
    • When in doubt, submit a PA with full documentation described in other callouts
    Note

    Reimbursement Risk Noted in Real‑World Data

    Real‑world analyses indicate reimbursement risk for some device indications (eg, dTMS for OCD was often paid out‑of‑pocket in early post‑marketing practice). Providers should confirm coverage and prior authorization policies before treatment.

    • dTMS for OCD had limited insurance reimbursement early post‑marketing — verify coverage and PA needs
    • Document patient financial counseling when coverage is uncertain
    Denial Risk

    Evidence Insufficiency May Trigger Denial

    Evidence insufficiency (small, short trials, heterogeneity, inadequate blinding) may trigger denials for indications where clinical benefit is uncertain. PA reviewers should require robust outcome measures and longer follow‑up in requests for coverage.

    • Provide RCT-level evidence showing meaningful clinical outcomes and durability to avoid denials
    • When only small/short trials exist, include a plan for outcomes monitoring and retreatment criteria
    Denial Risk

    Evidence Quality Limits Coverage Confidence

    Quality limits in the literature (risk of bias, small sample sizes, variable blinding) reduce confidence in efficacy estimates; reviewers should weigh study quality when adjudicating coverage and may deny when evidence quality is low.

    • Cite higher‑quality trials and meta‑analyses when available; note limitations of smaller, biased studies
    • Document how the requested protocol aligns with higher‑quality evidence
    Step Therapy

    Medication Trial Adequacy Note

    Trials of medications not approved in the United States do not count as adequate antidepressant or augmentation trials for the purposes of meeting prior‑treatment requirements.

    • Only FDA‑approved antidepressants and augmenting agents (or documented FDA‑approved augmentation strategies) count toward adequacy
    • Non‑U.S. drug trials should not be used to meet step‑therapy requirements
    Note

    References Segment — No Additional Authorization Rules

    This section contains references and does not itself specify additional authorization rules. Providers should use the references to support PA requests and to document the evidence base for the requested therapy.

    • Include pertinent citations from the References to support clinical rationale
    • References document the evidence base but do not replace required clinical documentation
    Documentation Required

    Required Documentation for Prior Authorization

    Required documentation for PA should include: psychiatrist‑confirmed diagnosis of severe MDD (or other target diagnosis) using standardized rating scales at baseline and serially; documentation of prior adequate trials (medication and augmentation) with doses and durations; contraindications; and the supervising psychiatrist’s order.

    • Baseline and ongoing validated rating scale scores (eg, MADRS, HDRS, BDI) with dates
    • Verification of prior antidepressant and augmentation trials (doses, dates, source)
    • Statement of contraindications and safety considerations
    Documentation Required

    Document Prior Treatment Resistance

    Prior treatment resistance documentation should specify the number, class, dose, and duration of prior antidepressant trials and any augmentation strategies tried or intolerances documented. When available, corroborate with pharmacy records or clinician notes.

    • List each antidepressant/augmentation agent, start/stop dates, maximum tolerated dose, and reason for discontinuation or failure
    • If trials involved non‑U.S. drugs, note they do not count toward adequacy
    Documentation Required

    Document Prior Treatments and Concurrent Medications

    Document prior treatments and concurrent medications. Many trials continued or restarted antidepressant therapy during TMS; PA requests should list current psychotropic medications and any concurrent therapies that will continue during TMS.

    • Provide a current medication list with doses and start dates, including antidepressants and augmentation agents
    • State whether medications will be held, changed, or continued during the TMS course
    Documentation Required

    Clinical Outcomes and Protocol Documentation

    Clinical outcomes and protocol documentation should include the selected outcome measures, planned timing of assessments, response/remission criteria, retreatment criteria, and safety monitoring plans. Outcome measures should be appropriate to the indication (eg, MADRS/HAMD for depression, UPDRS for Parkinson disease, THI for tinnitus).

    • Specify primary and secondary outcome measures and the schedule for assessments
    • Define response/remission thresholds and criteria for relapse or retreatment
    Documentation Required

    Outcome Measures and Follow‑Up Documentation

    Outcome measures and follow‑up documentation: include validated scales and planned follow‑up intervals to assess durability (eg, 3–6 month follow‑up when available). Provide plans for maintenance or tapering sessions and criteria for re‑introduction.

    • Baseline and serial validated scale scores with dates (eg, MADRS, HDRS, YBOCS, THI, UPDRS)
    • Planned follow‑up timeline and retreatment/maintenance strategy
    Documentation Required

    Safety Documentation Recommended

    Safety documentation is recommended. Include seizure risk assessment, contraindications (eg, cranial metal), adverse event monitoring plan, and procedures for seizure management when applicable. For devices producing loud sounds (eg, dTMS), note hearing protection plans.

    • Assess and document seizure history and baseline seizure frequency when relevant
    • Document plans for monitoring adverse events and emergency procedures during sessions
    Documentation Required

    Clinical Documentation Supporting TMS Use

    Clinical documentation supporting TMS use should include the indication, modality, exact target region, treatment parameters, supervising clinician, and expected clinical endpoints. For navigated TMS mapping, include mapping parameters and how mapping results will be used in care.

    • State modality (rTMS, dTMS, navigated TMS, tDCS/CES) and targeted brain region(s) with rationale
    • For navigated TMS, include mapping coordinates, motor hotspots, and integration with surgical planning if applicable
    Documentation Required

    Use of Y‑BOCS for OCD Outcome Documentation

    For OCD, the Yale‑Brown Obsessive Compulsive Scale (Y‑BOCS) is the primary outcome measure used in trials and registries. PA requests for dTMS/OCD should include baseline and planned serial Y‑BOCS assessments and define response criteria (commonly ≥30% reduction).

    • Provide baseline Y‑BOCS and planned post‑treatment Y‑BOCS schedule
    • Define response (eg, ≥30% reduction) and sustainment criteria
    Documentation Required

    Participant Characterization and Medication Status

    Participant characterization and medication status are important: document psychiatric comorbidities, severity, prior response patterns, and concurrent psychotropic medications, since these factors influence outcomes and interpretation of evidence.

    • Provide comorbidity list (eg, psychosis, substance use) and how these affect eligibility
    • List concurrent psychotropics and whether medication changes are planned during the TMS course
    Note

    Reference List Only — No Additional Documentation Rules

    Reference list only; this segment does not itself impose authorization or documentation rules. Use the references to support clinical rationale and cite when submitting prior authorization requests.

    • Include relevant citations from the References in PA submissions to support clinical justification
    Step Therapy

    Step‑Therapy Requirement

    Step‑therapy requirement: TMS for major depressive disorder is generally covered only after failed adequate pharmacotherapy — commonly defined as two antidepressants from different classes (or augmentation strategy) during the current episode; verify payer‑specific step‑therapy rules.

    • Two antidepressants from different classes each ≥8 weeks at adequate dose OR adequate augmentation strategy
    • Confirm whether prior trials occurred in the current depressive episode (typically within past 5 years)
    Step Therapy

    Step‑Therapy: Confirm Prior Medication Strategies Tried

    Confirm prior medication strategies tried as part of step‑therapy review. Evaluate whether medications were used at therapeutic doses and durations and whether augmentation (per Appendix definitions) was attempted before TMS.

    • Check adherence, dosing adequacy, and documentation for each trial
    • Augmentation is defined as two antidepressants with different mechanisms, or antidepressant plus FDA‑approved adjunct (antipsychotic, lithium, or T3)
    Documentation Required

    ECT Precedence in Some Treatment‑Resistant Cases

    ECT precedence in some treatment‑resistant cases: clinical guidelines note ECT as the most effective therapy for medication non‑responders. When ECT is clinically appropriate, document whether ECT was considered, attempted, contraindicated, or refused.

    • Document ECT consideration, contraindications, or patient refusal when relevant to choosing TMS
    • If ECT was deferred, provide rationale (eg, medical contraindications, patient preference)
    Prior Authorization

    Require Concurrent Conventional Rehabilitation When Indicated

    Require concurrent conventional rehabilitation for some neurologic indications (eg, post‑stroke motor recovery). Evidence often combined rTMS/tDCS with physical or occupational therapy; PA should specify concurrent rehab plans when applicable.

    • For stroke or motor rehabilitation, document planned neurorehabilitation modalities and timing relative to stimulation
    • Time‑locked stimulation combined with therapy should be described in the protocol
    Prior Authorization

    Consider Established Therapies Before Neuromodulation

    Consider established therapies first for indications where evidence is preliminary (eg, dementia-related symptoms, fibromyalgia). PA reviewers should expect documentation that guideline‑recommended conservative therapies were attempted prior to device therapy.

    • Document trials of exercise, cognitive therapies, standard pharmacologic options, or other guideline‑recommended care
    • Explain why TMS/tDCS is being pursued despite existing standard therapies
    Note

    No Explicit Step‑Therapy Rules Provided in References

    No explicit step‑therapy rules are provided in the references segment; payers should apply the policy’s step‑therapy requirements and require documentation described elsewhere in this section.

    • If payer uses different step‑therapy rules, follow payer‑specific protocols
    • References do not replace documented medication trials and augmentation evidence required for PA
    Prior Authorization

    Placement After Inadequate Response to First‑Line Therapy

    Placement after inadequate response to first‑line therapy: several authors recommend dTMS/rTMS as an option for patients who have not responded adequately to pharmacologic and psychological interventions. Document the first‑line therapies tried and the rationale for escalation to TMS.

    • Explain prior psychotherapy and pharmacotherapy, including durations and outcomes
    • Provide objective measures showing inadequate response
    Documentation Required

    Document Prior Conservative Therapies

    Document prior conservative therapies for non‑depression indications (eg, peripartum depression, chronic pain). Include prior psychotherapies, medications when appropriate, rehabilitation, and reason for their insufficiency.

    • List conservative treatments tried, dates, and responses
    • For peripartum depression, document counseling on medication risks/benefits and why TMS is preferred or necessary
    Documentation Required

    Augmentation Therapy Definition

    Augmentation therapy is defined as any of: two FDA‑approved antidepressants with different mechanisms used concomitantly; an FDA‑approved antidepressant plus a second‑generation antipsychotic approved for augmentation; antidepressant plus lithium; or antidepressant plus T3. Documentation of adequate augmentation (dose and duration) counts toward meeting prior‑treatment requirements.

    • Provide agent names, doses, dates, and objective response measures for augmentation trials
    • Only FDA‑approved augmentation strategies count toward adequacy
    Step Therapy

    Step‑Therapy Adequacy

    Step‑therapy adequacy: medication trials using drugs not approved in the U.S. do not qualify as adequate trials of antidepressants or augmenting agents. PA requests relying on non‑U.S. medication trials should supply alternative evidence of adequate treatment attempts.

    • Verify FDA approval status for agents cited as adequate trials
    • If non‑U.S. agents were used, provide documented attempts with FDA‑approved alternatives
    Note

    No Step‑Therapy Rules in References Segment

    No step‑therapy rules appear in the References segment; use the policy’s clinical criteria and Appendix definitions to adjudicate adequacy and step‑requirements for PA.

    • Apply the policy’s defined criteria for adequate trials and augmentation rather than relying solely on referenced studies

    Definitions and Terminology

    rTMS — Repetitive transcranial magnetic stimulation
    TermRepetitive transcranial magnetic stimulation (rTMS): noninvasive method using repeated magnetic pulses to modulate cortical excitability
    Mechanism notesStimulation parameters (frequency, intensity, pulse duration, site) determine excitatory or inhibitory effects
    SettingUsually performed in an outpatient setting; does not require anesthesia
    Current depressive episode (for policy purposes)
    Policy definitionCurrent depressive episode: the most recent onset of acute depressive symptoms (used to define timeframe for prior treatment trials)
    DocumentationSeverity should be measured at baseline with a validated depression rating scale and monitored throughout treatment
    RelevancePrior antidepressant trials are counted within the current depressive episode (typically within past 5 years per policy)
    Treatment-resistant depression (TRD)
    Core definitionTreatment‑Resistant Depression (TRD): depression failing to respond to at least one adequate antidepressant trial in the current episode; trials and regulatory language commonly study patients with ≥1 failed trial
    Typical trial requirementMost controlled trials required failure of ≥1 and commonly ≥2 adequate antidepressant medication trials
    ImplicationTRD populations are those enrolled in many pivotal rTMS/dTMS trials and inform FDA indications and coverage considerations
    Treatment‑Resistant Depression (TRD) — definition variant
    Alternative definitionTRD often operationalized as failure of one or more, typically two or more, adequate antidepressant trials in the current episode as commonly required by TMS trials
    Research noteHeterogeneous TRD definitions across studies limit cross-trial comparisons and interpretation of relapse/maintenance data
    Coverage impactConsistent definition of adequate trials is needed for eligibility and prior-authorization documentation
    dTMS — Deep transcranial magnetic stimulation
    TermDeep transcranial magnetic stimulation (dTMS): an H‑coil approach intended to stimulate deeper cortical and subcortical regions
    Clinical useStudied and FDA-cleared device (Brainsway) for OCD; also studied in MDD trials as monotherapy/adjunct
    Typical courseCommonly studied courses approximate daily sessions over ~4–6 weeks (eg, 20–29 sessions) with maintenance schedules in some protocols
    iTBS — Intermittent theta burst stimulation
    DefinitionIntermittent theta-burst stimulation (iTBS): an excitatory rTMS protocol consisting of short bursts repeated intermittently; evaluated as a noninferiority alternative to conventional 10‑Hz rTMS
    Protocol contextUsed in trials applying brief bursts to language or motor areas; can reduce session duration compared with conventional protocols
    Clinical trial noteiTBS was compared to 10‑Hz rTMS in a large noninferiority trial (N=388) informing response trajectories and scheduling
    tDCS — Transcranial direct current stimulation
    DefinitionTranscranial direct current stimulation (tDCS): noninvasive cranial electrical stimulation delivering weak direct current (anodal/cathodal) to modulate cortical excitability
    MechanismModulates excitability without directly inducing neuronal discharges; can increase excitability on one hemisphere while decreasing the other
    Evidence noteInvestigated for disorders of consciousness, cognitive modulation in dementia, and rehabilitation; long-term clinical benefit remains unproven
    sTMS — Single‑pulse transcranial magnetic stimulation
    DefinitionSingle‑pulse transcranial magnetic stimulation (sTMS): single‑pulse TMS used acutely and prophylactically (eg, for migraine); has received FDA approval for acute and prophylactic migraine use
    Use caseApplied in migraine protocols for abortive and preventive treatment in some trials and observational studies
    Adverse eventsReported adverse events are infrequent and include lightheadedness, tingling, tinnitus
    rTMS — Repetitive transcranial magnetic stimulation (technical)
    Technical definitionrTMS: repetitive delivery of magnetic pulses at varying frequencies and cortical targets to modulate cortical excitability
    Parameter dependenceEfficacy depends on frequency, intensity (often referenced to motor threshold), pulse number, target site, and session count
    Clinical implicationProtocol deviations (eg, intensity below 120% motor threshold) may reduce effectiveness and affect coverage decisions
    Low-frequency rTMS (LF-rTMS)
    DefinitionLow‑frequency rTMS (LF‑rTMS): stimulation ≤ 1 Hz, often applied to the motor cortex of the unaffected hemisphere to reduce contralesional excitability
    Typical useUsed in stroke and some movement disorder protocols to inhibit overactive contralesional cortex
    Evidence noteSome meta-analyses report greater effect sizes for LF‑rTMS in specific stroke subgroups
    High-frequency rTMS (HF-rTMS)
    DefinitionHigh‑frequency rTMS (HF‑rTMS): stimulation > 1 Hz, often applied to motor cortex of the affected hemisphere to increase ipsilesional excitability
    Typical antidepressant useHF‑rTMS to left DLPFC (eg, 10 Hz at ~120% motor threshold, ~3,000 pulses/session) is a common antidepressant protocol
    Clinical noteHF‑rTMS protocols appear in many positive trials but durability of effect varies across studies
    Intermittent theta-burst stimulation (iTBS) — definition
    DefinitionIntermittent theta‑burst stimulation (iTBS): excitatory rTMS protocol using short bursts of stimulation repeated intermittently
    Trial contextUsed as an abbreviated protocol compared with conventional 10‑Hz rTMS in noninferiority trials
    ApplicationApplied in language and motor-area stimulation studies (eg, iTBS for aphasia protocols)
    HF-rTMS — High-frequency rTMS
    TermHF‑rTMS: high‑frequency repetitive transcranial magnetic stimulation (stimulation >1 Hz) commonly used to increase cortical excitability
    Antidepressant protocolCommonly applied to left DLPFC (eg, 10 Hz, 120% MT, ~3,000 pulses/session) in MDD trials
    Evidence notePositive short‑term antidepressant effects reported; long‑term durability uncertain
    CES — Cranial electrical stimulation (CES)
    DefinitionCranial electrical stimulation (CES): application of TENS‑type electrical stimulation to the head
    Evidence summarySystematic reviews conclude evidence is insufficient for clinically important effects across multiple indications; trials generally small with risk of bias
    SafetyLow‑strength evidence suggests CES does not cause serious side effects but clinical benefit remains unproven for most indications
    MEP — Motor‑evoked potentials (MEP)
    DefinitionMotor‑evoked potentials (MEP): physiologic responses used to measure cortico‑spinal tract function induced by TMS stimulation
    UseMEPs employed in navigated TMS mapping and intra‑operative planning; changes correlate with motor pathway integrity
    Role in studiesMEP measures used as outcome or physiologic correlates in stroke and motor‑recovery trials
    Navigated TMS — image‑guided technique for mapping and planning
    DefinitionNavigated TMS: image‑guided (eg, MRI) TMS technique for mapping and planning stimulation to precise cortical locations
    Clinical applicationsUsed for pre‑operative motor and language mapping and for individualized tractography seed selection
    LimitationsEvidence for diagnostic effectiveness is limited by small studies; utility for improving health outcomes not yet established
    tDCS — Transcranial direct current stimulation (definition)
    DefinitiontDCS: noninvasive cranial electrical stimulation delivering weak direct current (anodal/cathodal) over cortical regions to modulate excitability
    Mechanistic noteDoes not directly evoke neuronal discharges but alters cortical excitability and plasticity potential
    Clinical contextsStudied for disorders of consciousness, cognitive enhancement, and rehabilitation with transient effects in some trials
    nTMS — navigated transcranial magnetic stimulation (pre-op mapping)
    DefinitionnTMS: navigated transcranial magnetic stimulation using neuronavigation for functional motor and language mapping prior to brain surgery
    Clinical rolenTMS‑based mapping has influenced surgical strategy and tractography seed selection in multiple observational studies
    Evidence caveatLarger validation studies and demonstration of improved patient outcomes are limited
    dTMS — deep transcranial magnetic stimulation (H‑coil) for OCD
    Device and indicationdTMS (H‑coil) received FDA marketing authorization for OCD based on randomized trials targeting mPFC/ACC
    Clinical outcome (OCD)In randomized trials using H7/dmPFC coil, response commonly defined as ≥30% reduction in Y‑BOCS and active dTMS showed higher response vs sham
    Typical courseDaily treatments for ~6 weeks (commonly 29 sessions) with individualized symptom provocation used in trials
    Response (OCD) — Y‑BOCS >=30% reduction definition
    Response definition (OCD)Response commonly defined as ≥30% reduction in Yale‑Brown Obsessive Compulsive Scale (Y‑BOCS) score from baseline
    Trial outcomesRandomized dTMS trials reported response rates ~38% active vs ~11% sham at end of treatment with maintained differences at follow‑up
    DocumentationSerial Y‑BOCS measurement baseline and post‑treatment recommended to define response and durability
    dTMS H7‑coil target — dmPFC/ACC target description
    Target descriptiondTMS H7‑coil target: dorso‑medial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC) configuration used in OCD trials
    Stimulation strategyTrials used symptom provocation immediately prior to stimulation to enhance targeting relevance
    ContraindicationsDevice contraindicated with metallic objects/implanted stimulators in or near the head; ear protection and seizure history precautions required
    Deep TMS (DTMS) — non‑invasive deeper stimulation
    DefinitionDeep TMS (DTMS): non‑invasive approach using higher‑intensity/high‑frequency protocols and specialized coils to stimulate deeper cortical/subcortical networks
    ApplicationsStudied for MDD, OCD, and substance use disorders with variable evidence across indications
    Protocol featuresOften uses HF protocols (eg, 10–20 Hz at 100–120% MT) delivered over multiple daily sessions (10–29 sessions typical in trials)
    TMS‑EEG / PCI — combined modality definition
    DefinitionTMS‑EEG / Perturbational Complexity Index (PCI): combined TMS and EEG modality measuring cortical responses; PCI is a metric to differentiate states like UWS vs MCS
    Clinical statusPromising research tool for disorders of consciousness but not yet established for routine clinical use
    Evidence noteStudies demonstrate potential diagnostic utility; further validation required before clinical implementation
    Non‑invasive brain stimulation (NIBS)
    DefinitionNon‑invasive brain stimulation (NIBS): umbrella term including TMS, dTMS, iTBS, sTMS, tDCS, and CES used to modulate brain function noninvasively
    ScopeApplied across psychiatric, neurologic, pain, and rehabilitation indications with modality‑specific evidence profiles
    Evidence caveatStrength and durability of effects vary by indication and modality; many indications remain investigational
    Cranial electrical stimulation (CES) — definition and evidentiary note
    DefinitionCranial electrical stimulation (CES): form of non‑invasive electrical stimulation applied to the head (TENS‑type); considered separately from TMS modalities
    Evidentiary noteSystematic reviews (eg, Shekelle et al) found insufficient evidence for clinically important effects for fibromyalgia, headache, pain, depression, or insomnia; low‑strength signals for anxiety/depression only
    SafetyLow‑strength evidence suggests CES does not cause serious adverse events, but trials often small with high risk of bias

    Treatment Modalities and Modifications

    Session Limits and Scheduling

    TMS sessions — 30 + 6 tapering
    Standard courseTypical TMS treatment course: up to 30 sessions over 6 weeks plus 6 tapering sessions (36 total)
    Delivery cadenceSessions are generally delivered daily (5 days/week) during the acute course
    Review for extra sessionsAdditional sessions beyond the 36‑session course may be reviewed for medical necessity
    rTMS treatment sessions — Daily sessions
    SchedulingrTMS is typically delivered as daily sessions (5 days/week) over the acute treatment course
    Accelerated protocolsSome studies report twice‑daily sessions over shorter intervals (eg, 2 weeks) in accelerated protocols
    Course variabilityTotal number of sessions in trials ranges (20–30 typical; examples include 20, 22, 29 sessions depending on protocol)
    rTMS session schedules — accelerated or maintenance clustering
    Accelerated schedulesTwice‑daily sessions have been used in accelerated protocols (eg, 10–14 days) in small trials
    Maintenance clusteringMonthly clustered series (eg, 5 sessions monthly) have been studied in observational maintenance reports
    Protocol noteScheduling varies by study and indication; prior‑authorization should specify planned schedule
    rTMS sessions (e.g., 5–20 sessions described in trials)
    Trial rangesReported randomized trial session counts vary broadly (eg, 5–20 sessions described across tinnitus and other trials)
    Protocol dependencyNumber of sessions and spacing are protocol‑dependent and influence outcomes in many indications
    DocumentationPrior‑authorization should include the proposed number of sessions and rationale referencing supporting trials where available
    Examples of reported study protocols
    ExamplesExamples reported include: 10 sessions over 2 weeks (accelerated), 22 sessions over 15 days (inpatient protocol), and 10 sessions delivered 3 days/week in some studies
    ContextThese example schedules derive from heterogeneous study protocols and are illustrative rather than standardized
    ImplicationProviders should align proposed schedules with evidence for the specific indication in authorization requests
    rTMS/dTMS treatment courses as reported in clinical studies — 20 sessions common
    Typical acute courseMany rTMS/dTMS clinical studies report treatment courses of approximately 20 sessions in efficacy evaluations
    dTMS coursesdTMS OCD and some MDD trials commonly used 29 sessions in their study protocols
    Course intentStudy‑based course lengths informed regulatory clearance and real‑world treatment planning
    dTMS sessions (commonly studied course) — 29
    Commonly studied coursedTMS courses for OCD and some trials commonly comprised 29 sessions delivered over ~6 weeks
    Real‑world dataRegistry and clinical‑practice reports often reference 29 sessions as the typical endpoint for initial response assessment
    Extended treatmentSome non‑responders in real‑world series showed continued improvement with treatment extended beyond 29 sessions

    Revision History and References

    2001-04-13policy_effective

    Policy originally effective.

    2024-02-16last_review

    Policy most recently reviewed on this date.

    2024-05-09next_reviewLatest

    Next scheduled policy review date.